Latest filings (excl ownership)
15-12G
Securities registration termination
27 Jun 23
25-NSE
Exchange delisting
16 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jun 23
POSASR
Automatic shelf registration (post-effective amendment)
16 Jun 23
8-K
Completion of Acquisition or Disposition of Assets
16 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
DEFA14A
Additional proxy soliciting materials
6 Jun 23
DEFA14A
Additional proxy soliciting materials
23 May 23
8-K
Other Events
23 May 23
DEFM14A
Proxy related to merger
16 May 23
10-Q
2023 Q3
Quarterly report
9 May 23
8-K
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress
9 May 23
PREM14A
Preliminary proxy related to merger
28 Apr 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
DEFA14A
Additional proxy soliciting materials
17 Apr 23
8-K
Entry into a Material Definitive Agreement
17 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
28 Feb 23
8-K
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
28 Feb 23
10-K
2022 FY
Annual report
28 Feb 23
8-K
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
9 Dec 22
424B5
Prospectus supplement for primary offering
9 Dec 22
424B5
Prospectus supplement for primary offering
7 Dec 22
8-K
Other Events
7 Dec 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
9 Nov 22
8-K
Other Events
3 Oct 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
11 Aug 22
8-K
Other Events
26 Jul 22
8-K
Other Events
8 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
20 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
8-K
Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress
12 May 22
8-K
Entry into a Material Definitive Agreement
1 Apr 22
S-3ASR
Automatic shelf registration
1 Apr 22
DEFA14A
Additional proxy soliciting materials
1 Apr 22
DEF 14A
Definitive proxy
1 Apr 22
10-K
2021 FY
Annual report
9 Mar 22
Latest ownership filings
4
Martin Hendrix
16 Jun 23
4
James Laur
16 Jun 23
4
Mark Stenhouse
16 Jun 23
4
Mary T Szela
16 Jun 23
4
Mark C. McKenna
16 Jun 23
4
Judith L Swain
16 Jun 23
4
JOSEPH C PAPA
16 Jun 23
4
Fred Hassan
16 Jun 23
4
Keith W Marshall
16 Jun 23
4
Helen C. Adams
16 Jun 23
4
Mark C. McKenna
2 Jun 23
4
Keith W Marshall
2 Jun 23
4
Mark Stenhouse
2 Jun 23
4
JOSEPH C PAPA
2 Jun 23
4
Mary T Szela
19 May 23
4
Judith L Swain
19 May 23
4
JOSEPH C PAPA
19 May 23
4
James Laur
19 May 23
4
Martin Hendrix
19 May 23
4
Fred Hassan
19 May 23
4
Helen C. Adams
19 May 23
4
Keith W Marshall
7 Apr 23
4
Mark C. McKenna
17 Mar 23
4
Keith W Marshall
8 Mar 23
4
Change in insider ownership
8 Mar 23
SC 13G/A
Cedars Sinai Intellectual Property Co
8 Mar 23
144
Notice of proposed sale of securities
8 Mar 23
4
Mark C. McKenna
3 Mar 23
4
Keith W Marshall
17 Feb 23
4
Mark C. McKenna
17 Feb 23
SC 13G/A
Cedars Sinai Intellectual Property Co
17 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
Cormorant Asset Management, LP
14 Feb 23
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
4
Keith W Marshall
19 Jan 23
4
Mark C. McKenna
19 Jan 23
4
Keith W Marshall
20 Dec 22